simmitecanib

Simmitecanib (also known as ximeteinib) is an orally bioavailable, small-molecule multi-kinase inhibitor developed by the Shanghai Institute of Materia Medica (SIMM). It is designed to inhibit several receptor tyrosine kinases involved in tumor angiogenesis and proliferation, specifically targeting the vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and the mast/stem cell growth factor receptor (c-Kit). By blocking these pathways, simmitecanib aims to disrupt the tumor's blood supply and inhibit direct proliferative signaling. It is currently being evaluated in Phase I/II clinical trials, notably in combination with the HER2-targeted antibody-drug conjugate DP303c, for the treatment of HER2-low recurrent or metastatic breast cancer and other advanced solid tumors.

Other names

ximeteinibximeteinib hydrochlorideximeteinib hydrochloride tablets